open access

Vol 71, No 3 (2020)
Clinical Vignette
Published online: 2020-03-10
Submitted: 2020-01-22
Accepted: 2020-02-21
Get Citation

Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer

Havva Sezer, Dilek Yazıcı, Oğuzhan Deyneli, Çişel Meriçöz, Ayla Esin, Emrah Alper
DOI: 10.5603/EP.a2020.0012
·
Pubmed: 32154575
·
Endokrynologia Polska 2020;71(3):283-284.

open access

Vol 71, No 3 (2020)
Clinical Vignette
Published online: 2020-03-10
Submitted: 2020-01-22
Accepted: 2020-02-21

Abstract

Not required for Clinical Vignette.

Abstract

Not required for Clinical Vignette.

Get Citation

Keywords

empagliflozin; euglycaemic diabetic ketoacidosis; pancreas cancer

About this article
Title

Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer

Journal

Endokrynologia Polska

Issue

Vol 71, No 3 (2020)

Pages

283-284

Published online

2020-03-10

DOI

10.5603/EP.a2020.0012

Pubmed

32154575

Bibliographic record

Endokrynologia Polska 2020;71(3):283-284.

Keywords

empagliflozin
euglycaemic diabetic ketoacidosis
pancreas cancer

Authors

Havva Sezer
Dilek Yazıcı
Oğuzhan Deyneli
Çişel Meriçöz
Ayla Esin
Emrah Alper

References (5)
  1. U.S. Food and Drug Administration. FDA Adverse Events Reporting System — Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System 2019.
  2. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166): 31–39.
  3. Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018; 20(1): 25–33.
  4. Limenta M, Ho CSC, Poh JWW, et al. Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors. Clin Drug Investig. 2019; 39(7): 683–690.
  5. Markabawi D, Kondapi D, Tambe V, et al. When it is not just DKA; diabetic ketoacidosis as a first presentation of pancreatic adenocarcinoma. Am J Emerg Med. 2018; 36(9): 1720.e1–1720.e2.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl